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Abstract
Laminin-211 is a cell-adhesion molecule that is strongly expressed in the basement membrane of skeletal muscle.
By binding to the cell surface receptors dystroglycan and integrin a7b1, laminin-211 is believed to protect the
muscle fiber from damage under the constant stress of contractions, and to influence signal transmission events.
The importance of laminin-211 in skeletal muscle is evident from merosin-deficient congenital muscular dystrophy
type 1A (MDC1A), in which absence of the a2 chain of laminin-211 leads to skeletal muscle dysfunction. MDC1A is
the commonest form of congenital muscular dystrophy in the European population. Severe hypotonia, progressive
muscle weakness and wasting, joint contractures and consequent impeded motion characterize this incurable
disorder, which causes great difficulty in daily life and often leads to premature death. Mice with laminin a2 chain
deficiency have analogous phenotypes, and are reliable models for studies of disease mechanisms and potential
therapeutic approaches. In this review, we introduce laminin-211 and describe its structure, expression pattern in
developing and adult muscle and its receptor interactions. We will also discuss the molecular pathogenesis of
MDC1A and advances toward the development of treatment.
Introduction
The basement membrane is a thin scaffold of specific
extracellular protein networks associated with various
cell types, including muscle fibers. This specialized fra-
mework of extracellular matrix (ECM) provides impor-
tant functional cues to cells. Laminins comprise a family
of glycoproteins that are major components of all base-
ment membranes [1]. Occurrence of a laminin molecule
in hydra, one of the oldest multicellular organisms, indi-
cates that laminins existed already 600 million years ago
[2]. Laminins are large (400-900 kDa) heterotrimeric
molecules composed of one a,o n eb and one g subunit
in a cruciform or T-shaped appearance. To date, five a,
three b and three g chains have been characterized.
They represent the products of distinct genes that
evolved by duplication and recombination of ancestral
a, b and g genes, hence they share sequence similarity.
Currently, the trimers are named according to the com-
position of the a, b and g chains and more than 15 dif-
ferent laminin isoforms, with various arrangements of
laminin subunits, have been identified [3-5]. The first
laminin isoform, laminin-111, was discovered more than
30 years ago in the Engelbreth-Holm-Swarm tumor [6].
Subsequently, laminin-211 (composed of a2, b1a n dg1
chains) (Figure 1) was isolated from placenta and was
originally called merosin [7]. It is now well established
that laminin-211 is the main laminin isoform in skeletal
muscle [8,9], and identification of laminin a2c h a i n
mutations in a severe form of congenital muscular dys-
trophy (merosin-deficient congenital muscular dystro-
phy; MDC1A) showed the importance of laminin-211
for normal muscle function [10].
Laminin a2 chain gene and protein
The LAMA2 gene is located on chromosome 6q22-23 in
humans and on chromosome 10 in mice [10-12]. The
gene is composed of 65 exons that encode a protein with
a predicted molecular mass of 390 kDa. However, it is
cleaved by a furin-like convertase into a 300 kDa N-
terminal segment and a 80 kDa C-terminal segment,
which remain non-covalently associated [13-15].
Whether this proteolytic processing has functional conse-
quences in muscle in vivo is not known. The laminin a2
chain has a similar domain organization to that of the
other laminin chains, with several globular and rod-like
regions. Domains LN, L4a and L4b form globular struc-
tures separated by rod-like spacers of LE domains
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coiled-coil domain, and finally, the C-terminal end is
composed of five homologous laminin globular (LG)
domains (LG1 to LG5) (Figure 1) [3]. Key biologic activ-
ities have been mapped to several of these domains. The
LN domain is essential for laminin polymerization into
supramolecular networks and consequently for incor-
poration into basement membranes [16], and mutations
in this domain reduce the ability of polymer formation
[17]. The coiled-coil domain is involved in the formation
of laminin heterotrimers, and the laminin a2c h a i nc a n
assemble with the b1, g1, b2a n dg3 chains to form lami-
nins 211, 221 and 213 [5]. The laminin a2L Gd o m a i n s
at the C-terminus bind cellular receptors (dystroglycan
and integrin a7b1) [15,18], and such interactions are
required for adhesion, basement-membrane assembly
and downstream signaling events [19,20].
Laminin-211 and other laminins in developing muscle
Myogenesis is a complex multistep process, but it has
been found that muscle morphogenesis is strongly
guided by ECM cues [21]. There is robust evidence that
laminins are important for synaptogenesis [22-26], but
their precise function in myogenesis is still not known.
Each immature murine somite is surrounded by a lami-
nin-111-rich basement membrane [27]. While entering
the myotome during somite differentiation, muscle pro-
genitors begin to form the myotomal basement mem-
brane that separates the myotome and sclerotome [28],
and laminin-111 seems to be fundamental for the initia-
tion of its assembly, at least in mice [29]. After the
initial myogenic events, formation of primary and sec-
ondary myotubes takes place. Basement-membrane
remodeling and differential expression of laminin subu-
nits is tightly correlated with these events. During the
first fusion events in mice at embryonic day (E)11, lami-
nin-211 and laminin-511 are the major heterotrimers of
the newly formed basement membrane (the laminin a1
chain is still present at E11.5, but it is largely restricted
to the ends of myotubes) [9]. Just before the fusion of
secondary myotubes (at E14), expression of the laminin
a4 chain increases dramatically, and it is deposited
throughout the secondary myotube basement membrane
by E15 [9]. In developing human muscle, the laminin a2
chain is present from around the seventh week of gesta-
tion, reaching maximum expression levels at week 21
[30,31], and the laminin a4 chain is strongly expressed
at week 16 [32]. Additionally, the laminin a5s u b u n i t
was shown to be a major laminin a chain during myo-
genesis in humans, whereas the laminin a1 subunit was
detected only in the developing myotendinous junction
(MTJ) [31,33]. It is noteworthy that the laminin compo-
sition is also modified during development of specialized
muscle sites, such as the neuromuscular junction (NMJ)
and the MTJ [9,31,34].
Further changes om the laminin array in muscle base-
ment membrane occur perinatally both in human and
mouse as myotubes mature into myofibers. The levels of
laminin a4a n da5 subunits markedly decrease at birth
and are not detectable at the sarcolemma by the end of
the first postnatal week [9,32,35]. Thus, the laminin a2
subunit is the only laminin a chain expressed in the extra-
synaptic basement membrane. Interestingly, in vitro stu-
dies with myogenic cell lines found that both the laminin
a1a n da2 chains possess myogenic properties, performing
both shared and specific tasks in myogenesis [36,37].
Although several laminins are expressed in a distinct
manner during myogenesis, none of the laminin a
Figure 1 Scheme of laminin-211 heterotrimeric structure.
Laminin a2 chain is depicted in red, b1 in green and g1 in blue.
Laminin a2 chain consists of: the N terminal globular domain (LN);
tandem rod domains of epidermal growth factor (LEa, LEb, LEc),
separating the LN, L4a and L4b globular domains; the laminin
coiled-coil (LCC) domain that tangles with the LCC domains of the
b1 and g1 chains; and the C-terminal laminin globular (LG) domains.
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Myogenesis occurs normally in patients and mice lack-
ing laminin a2 subunit [11,12,40-43], even though myo-
fibers are smaller at birth in patients with MDC1A
[40,41]. It is possible that laminin a4a n d / o ra5c o u l d
compensate for absence of the laminin a2c h a i ni n
developing muscle, and studies of muscles devoid of sev-
eral a chains would be therefore be interesting. Lami-
nins containing the a2 chain are instead crucial in adult
muscle, and this topic will be discussed in more detail
in later sections.
Laminin-211 and other laminins in mature muscle
The basement membrane surrounding the mature mus-
cle cell (Figure 2A,B) contains laminins 211 and 221
[8,9,44] (Figure 2C). To form a strongly crosslinked
basement membrane, which provides significant struc-
tural support to muscle cells [45], laminins 211 and 221
Figure 2 Basement membrane (BMs) of the neuromuscular system. (A) Electron microscopy of BMs in normal diaphragm muscle (SM,
skeletal muscle). Red arrow = BM, blue arrow = sarcolemma, yellow arrowhead = sarcomere (cross-section), green arrowhead = collagen fibrils
in the interstitial matrix (ECM). (B) Scheme of the motor innervation with distinct BMs. The BMs comprise a continuous layer around muscle
fibers and Schwann cells of the peripheral nervous system (red layer), and there is a different composition of laminin chains and other
extracellular matrix components at the neuromuscular junction (NMJ) (yellow layer). Muscle fibers and satellite cells are surrounded by an
extrasynaptic BM containing mainly laminin-211. At the NMJ, laminins 221, 421 and 521 are the prominent laminin isoforms. Schwann cells at
the NMJ and myelinating Schwann cells (blue = myelin) that frame the axon of the motor nerve are surrounded by a BM with slightly different
laminin composition (laminins 211 and 411 as well as 221 and 421). (C) Laminin a2 chain expression in BMs of the neuromuscular system
(immunofluorescent staining with the 4H8-2 antibody generated against the N-terminal domain of the laminin a2 chain). The laminin a2
subunit (red staining) forms the backbone of BMs that surround muscle fibers (extrasynaptic BMs) (purple arrow),underlie the NMJ (yellow) (the
co-localization of laminin a2 chain (red staining) and acetylcholine receptors (green staining with a-bungarotoxin) is also shown), surround
Schwann cells of the intramuscular peripheral nerve (blue arrow), surround muscle spindles (white arrowhead) and underlie the myotendinous
junction (MTJ) (white arrows). Inset shows a higher magnification of the MTJ.
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ing nidogens (which in turn (connect) the laminin net-
work to the collagen network), fibulins and agrin
[18,46]. There are also structurally and functionally spe-
cialized basement membranes within the skeletal muscle
compartment (Figure 2B,C). The sites of muscle contact
with motor nerves (the NMJ) encompass three basement
membranes, each with a distinct laminin expression pat-
tern; the extrasynaptic basement membrane, the base-
ment membrane of the synaptic cleft, and the Schwann
cell basement membrane (Figure 2B). The basement
membrane within the synaptic cleft contains laminins
221, 421 and 521 at the sites of concentration of acetyl-
choline receptors (primary clefts), whereas the sites of
concentration of sodium channels (folds of secondary
clefts) include laminins 221 and 421 [9]. Basement
membranes surrounding Schwann cells in the peripheral
nervous system include mainly laminins 211, 411 [47]
and probably 221 and 421 [48]. There is also a specia-
lized junction where muscle abuts tendon (the MTJ)
and laminins 211 and 221 are strongly expressed at this
site [49,9] (Figure 2C).
Laminin-211 in the sarcolemmal basement membrane
is extremely important for maintenance and stabilization
of differentiated muscle [37,50], and absence of the
laminin a2 chain leads to muscular dystrophy in
humans and mice [10-12,40-43]. Subtle NMJ defects
have also been reported in laminin a2 chain-deficient
mice [51], but it is possible that these arise from muscle
abnormalities caused by the dystrophic process. The
laminin a4a n db2 chains, by contrast, have important
roles in the NMJ. Mice devoid of the laminin a4 and b2
chainshave abnormal neuromuscular (synapses)
[22,23,26], and laminin b2 chain deficiency in humans
(Pierson syndrome) is characterized by muscular and
neurologic defects in addition to kidney failure [52].
Laminin receptors in skeletal muscle
Transmembrane receptors that interact with laminin
networks, connecting them to the cytoskeleton and
intracellular signaling pathways, trigger the biologic
functions of laminins. The two major laminin-211/221
receptors in skeletal muscle are dystroglycan and integ-
rin a7b1 (Figure 3). Dystroglycan is a highly glycosy-
lated, ubiquitously expressed protein that consists of
two subunits, a-dystroglycan and b-dystroglycan [53]. In
muscle, it forms the backbone of the multisubunit dys-
trophin-glycoprotein complex (DGC) linking laminin-
211 to the intracellular components dystrophin and
actin [54,55]. It was recently found that a phosphory-
lated O-mannosyl glycan on a-dystroglycan is required
for laminin binding [56], which occurs through the LG
domains of the laminin a2 chain [18]. Both laminin a2
L G 1t o3a n dL G 4t o5b i n da-dystroglycan strongly
(whereas individual modules do not bind, except for
weak interactions with the LG3 domain) [14,18]. The
crystal structure has been solved for the laminin a2
LG4 to 5 domain, and the a-dystroglycan binding site in
the a2 LG4 to 5 domain has been defined [57]. Binding
to a-dystroglycan is calcium-dependent [55]. The struc-
ture of the mouse laminin a2L G 4t o5d o m a i ns h o w e d
that the two calcium ions, implicated in dystroglycan
binding, are located in LG4 and LG5, respectively, and
the extensive basic surface region between the calcium
sites is proposed to bind a-dystroglycan [57].
Integrin a7b1 is the second transmembrane unit that
links laminin-211 to the cytoskeleton [58-60] and bind-
ing occurs through the laminin a2L G 1t o 3d o m a i n
with involvement of the coiled-coil domain [14,15].
However, the adaptor molecules that connect integrin
a7b1 to the cytoskeleton remain to be identified [61],
although talin [62] and integrin-linked kinase [63] are
likely candidates. We also recently identified a novel
integrin a7b1 interacting protein (Cib2), whose expres-
sion in muscle is dependent on the presence of the
laminin a2 chain [64].
The significance of the laminin receptors for normal
muscle function is emphasized by the fact that muta-
tions in DGC components and post-translational defects
in dystroglycan processing and mutations in the integrin
a7 gene causes various forms of muscular dystrophy
and myopathy [65,66]. Hence, there is strong evidence
that both receptors contribute to linking laminin-211 to
the cytoskeleton and mediate the effects of laminin-211
on muscle integrity and function. It has been shown
that the two systems act synergistically [67,68], but sepa-
rate roles have also been delineated [69,70]. Both dystro-
glycan and integrin a7b1 contribute to force production,
but only dystroglycan is involved in anchoring the base-
ment membrane to the sarcolemma [69]. Furthermore,
different muscles may have different requirements for
the laminin-dystroglycan interaction as it may not be
crucial in diaphragm but important in limb muscle [70].
Nevertheless, many of the downstream events of the
laminin-211-receptor interaction remain to be eluci-
dated. Several signaling pathways may be affected, but
the importance of each of those pathways in skeletal
muscle is not obvious [71-76].
Finally, it should be noted that laminin-211 also binds
other cell-surface receptors, although dystroglycan and
integrin a7b1 may be considered as the major laminin-
211 receptors in skeletal muscle. These other receptors
include the syndecans and sulfated glycolipids [18,77].
Interestingly, sulfatides have been proposed to anchor
laminin-211 by binding to its LG domains to initiate
basement-membrane assembly and to engage the activa-
tion of receptors (dystroglycan and b1 integrins), at least
in Schwann cells [20].
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Laminin a2 chain-deficient muscular dystrophy
(MDC1A), showing autosomal recessive inheritance, was
recognized as a particular form of congenital muscular
dystrophy in 1994 when Tomé et al., found specific
absence of the laminin a2 chain in patients [41]. Shortly
after, the first causative mutations in the LAMA2 gene
were identified, and a number of mutations have subse-
quently been reported [10,78,79]. It is now clear that com-
plete laminin a2 chain deficiency leads to a severe
phenotype, whereas partial deficiency may lead to a severe
or a milder phenotype [80]. The estimated prevalence of
congenital muscular dystrophy is around 7 × 10
-6 [81],
and MDC1A accounts for approximately 40% of cases of
congenital muscular dystrophy in Europe [78,79]. The
clinical features of MDC1A include profound muscle
hypotonia at birth and generalized muscle weakness
accompanied by contractures that mostly affect the
elbows, hips knees and ankles, along with scoliosis, kypho-
sis, increased creatine kinase levels, and delayed motor
milestones (Figure 4). Patients may achieve unsupported
sitting, but very few attain ambulation. Common serious
complications of MDC1A include respiratory failure and
feeding difficulties. Importantly, treatment with noninva-
sive ventilation and gastrostomy can greatly improve
health. However, respiratory-tract infection is the com-
monest cause of death, which may occur in the first dec-
ade of life or anytime subsequently [78,79]. As the laminin
a2 chain is also expressed in the central nervous system
(CNS), peripheral nervous system and heart [8], these
tissues are also affected to various degrees in MDC1A.
Most patients (after 1 year of age) display white-matter
Figure 3 Laminin-211 receptors in muscle and their binding sites on the laminin a2 chain.L a m i n i na2 subunit binds dystroglycan and
integrin a7b1 via the laminin globular (LG) domains. LG1 to 3 and 4 to 5 bind a-dystroglycan, whereas only LG1 to 3 binds integrin a7b1.
Glycosylation of a-dystroglycan is important for laminin binding.
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resonance imaging, but these changes do not seem to be
associated with any particular functional impairment.
Structural brain changes have been reported in some
patients, and epilepsy may be present. Moreover, patients
have decreased peripheral nerve conduction velocity
because of myelination defects. Severe heart failure is rare
in MDC1A, but left ventricular dysfunction has been
reported in about 30% of patients [78,79,82]. No treatment
is currently available for this devastating disease.
Mouse models for laminin a2 chain deficiency
A number of mouse models for laminin a2c h a i nd e f i -
ciency exist, and in general they adequately model
human disease. In addition, they confirm the relation-
ship between laminin a2 chain expression and severity
of disease [83] (Table 1 and references therein). The dy/
dy mouse expresses reduced levels of an apparently nor-
mal laminin a2 chain, but the causative mutation
remains to be identified. The dy/dy mouse displays
moderate muscular dystrophy, peripheral neuropathy,
heart fibrosis and defects in CNS myelination [11,12,84].
The dy
2J/dy
2J mouse harbors a mutation in the N-
terminal (LN) domain, which leads to abnormal splicing
and slightly reduced expression of a laminin a2c h a i n
lacking this domain. These mice display a relatively mild
muscular dystrophy and peripheral neuropathy [85,86].
Two further mouse models have been generated by
homologous recombination: the dy
W/dy
W mouse
expresses small amounts of a truncated a2 chain lacking
the LN domain whereas the dy
3K/dy
3K mouse (Figure 5)
is completely deficient in the laminin a2c h a i n .B o t h
dy
W/dy
W and dy
3K/dy
3K mice develop severe muscular
dystrophy and die within a few weeks of age. They also
exhibit pronounced hind-leg lameness [42,43,83]. Never-
theless, it seems that the phenotype of the dy
3K/dy
3K
mouse is more severe than that of the dy
W/dy
W mouse,
and it could be that the residual laminin a2c h a i n
expression in dy
W/dy
W muscle is beneficial. The most
recently described mouse model is the dy
nmj417/dy
nmj417
mouse, in which a single point mutation in the LN
domain leads to normal levels of a mutated laminin a2
chain and mild muscular dystrophy [87].
Although it can be debated whether mice are reliable
as preclinical models for human disease, analyses of the
various laminin a2 chain-deficient mouse models have
led to a significant improvement in our understanding
of development of MDC1A. More importantly, they
have been valuable tools for the development of novel
therapeutic approaches for laminin a2 chain deficiency.
Figure 4 Clinical features of a patient with merosin-deficient congenital muscular dystrophy (MDC1A) with complete laminin a2 chain
deficiency. (A) Facial weakness with an open mouth and reduced facial expression. Patient has developed bilateral elbow-flexion contractures, a
fairly common sign in patients with MDC1A. (B) Bilateral knee-flexion contractures and lumbar hyperlordosis. (C) Truncal weakness and neck-
flexion weakness (lack of head control) when the patient is pulled up from a lying position. Informed consent was obtained from the patient’s
parents for publication of the photographs.
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Although the primary defect in MDC1A is known to be
loss of the laminin a2 chain, the secondary molecular
mechanisms ultimately leading to muscle degeneration
have yet to be determined. Absence of laminin a2f r o m
skeletal muscle gives rise to a marked dystrophic pattern
with muscle fiber-size variation (with atrophy predomi-
nance), central nucleation and extensive fibrosis
(Figure 6) [79]. Further features typical of MDC1A
include disrupted basement membranes [11] and
increased apoptosis [88,89]. It has been suggested that
the laminin a2 chain confers a structural link (by bind-
ing to dystroglycan) from the ECM to the cytoskeleton,
and that such linkage stabilizes the muscle-cell mem-
brane and protects it from contraction-induced damage
[90,91]. However, this hypothesis was challenged by Hall
et al. [92]. Using a zebrafish laminin a2-chain mutant,
they suggested that damage to the muscle fiber occurs
by mechanically induced fiber detachment in the
absence of sarcolemma rupture, and that detached fibers
undergo apoptosis. Nevertheless, cell membranes are
ruptured to some extent in animals with complete lami-
nin a2 chain deficiency [70] and it has been proposed
that laminin a2 chain binding to a-dystroglycan
strengthens the sarcolemmal integrity [69]. The down-
stream signaling events leading to apoptosis remain to
be deciphered, but recent data suggest that it includes
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-
Siah1-CBP/p300-p53 signaling [93]. However, there are
relatively few apoptotic fibers in laminin a2c h a i n -
deficient muscles [89,93], hence there must be other
mechanisms underlying the muscle wasting seen in
MDC1A. Both the ubiquitin-proteasome system and the
autophagy-lysosome pathway play key roles in protein
degradation in skeletal muscle cells [94]. Interestingly,
we recently found that increased proteasomal degrada-
tion is a feature of dy
3K/dy
3K muscle [95], and prelimin-
ary unpublished data indicate that there might also be
excessive autophagy in dy
3K/dy
3K muscle. Defects in
both of these degradative systems have also been found
in other muscular dystrophies. For example, Duchenne
muscular dystrophy pathogenesis may involve proteaso-
mal degradation of dystrophin and the DGC [96], and
autophagy is impaired (but not increased as in MDC1A)
in collagen VI-deficient muscular dystrophy [97].
At the molecular level, absence of the laminin a2
chain affects the expression and localization of several
other laminin chains and cell-surface receptors. In parti-
cular, expression of the laminin b2 chain is severely
reduced from the sarcolemmal basement membranes in
laminin a2 chain-deficient muscle [44]. Conversely,
laminin a4( a n da5 chain to some extent) is increased
at this site [9,98]. However, it does not seem to com-
pensate for the absence of the laminin a2c h a i n ,p r e -
s u m a b l yb e c a u s et h el a m i n i na4 chain cannot bind
a-dystroglycan [99], or possibly because that the laminin
a4 chain is not upregulated in sufficient amounts. In
extraocular muscles, which have a number of differences
from other skeletal muscles, the laminin a4 chain is
strongly expressed in the basement membrane adjoining
the sarcolemma, and its expression is further enhanced
in the extraocular muscle of dy
3K/dy
3K animals. Interest-
ingly, laminin a2 chain-deficient extraocular muscles are
spared from dystrophic changes, and it has been
hypothesized that binding of the laminin a4c h a i nt o
integrin a7b1 may protect the extraocular muscles from
damage [100,101].
Changes in the expression of laminin-211 receptors
might also contribute to the pathology of MDC1A. A dra-
matic decrease of integrin a7 subunit in muscle from
Table 1 Mouse models for laminin a2 chain deficiency
Mouse
model
Mutation/protein product Phenotype Ref
dy/dy Unknown spontaneous mutation/reduced
expression of seemingly normal a2 chain
Lethal within 6 months of age. Moderate muscular dystrophy;
peripheral neuropathy; defective central nervous system
myelination; hearing loss; aberrant thymocyte development
[11,12,84,121,122]
dy
2J/dy
2J Spontaneous mutation in LN domain
a/slightly
reduced expression of truncated a2 chain devoid
of LN domain
Normal lifespan. Mild muscular dystrophy; peripheral neuropathy [85,86 ]
dy
W/dy
W Knock- out/severely reduced expression of
truncated a2 chain devoid of LN domain
Lethal at 10 to 15 weeks of age. Severe muscular dystrophy;
peripheral neuropathy
[43,83]
dy
3K/dy
3K Knock-out/complete deficiency Lethal at 4 weeks of age. Severe muscular dystrophy; peripheral
neuropathy; impaired spermatogenesis; defective odontoblast
differentiation
[42,123-125]
dy
nmj417/
dy
nmf417
N-ethyl-N-nitrosourea-induced point mutation in
LN domain/normal levels
Normal lifespan. Mild muscular dystrophy; peripheral neuropathy [87]
dy
Pas/dy
Pas
(now
extinct)
Spontaneous retrotransposal insertion/severe
deficiency
Died at 13 weeks of age. Severe muscular dystrophy; peripheral
neuropathy
[126]
aLN = laminin N-terminal domain.
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and a striking impairment of its deposition at the sarco-
lemma [104], has been noted, suggesting that integrin
a7b1 signaling is abolished. By contrast, expression of
b-dystroglycan at the sarcolemma, is upregulated in lami-
nin a2 chain-deficient mouse muscle [104,105]. However,
conflicting data have been reported on a-dystroglycan
expression, with its production either not found to be
significantly affected by laminin a2 chain deficiency
[60,103] or shown to be moderately increased [104]. Moll
et al. and Jimenez-Mallebrera et al. reported severe reduc-
tion of a-dystroglycan core protein [105,106]. The precise
physiological outcomes of receptor alterations remain lar-
gely unknown, but altogether they point towards a central
position of laminin-211 in regulating the expression of
a7b1 and dystroglycan.
Figure 5 A dy
3K/dy
3Klaminin a2 chain-deficient mouse with a littermate (both 5 weeks old). Laminin a2 chain knockout mice have severe
muscle wasting and growth retardation, resulting in dramatically decreased weight. Hind-limb paralysis (depicted with arrow), a result of
peripheral neuropathy, is often seen before death.
Figure 6 Dystrophic features of laminin a2 chain muscle. Hematoxylin and eosin staining of triceps and diaphragm cross-sections from a
3.5-week-old dy
3K/dy
3K mouse reveals fiber-size variability with predominance of small atrophic fibers. Regenerating fibers with centrally located
nucleus and wide-spread fibrosis (green arrows) are also hallmarks of laminin a2 chain-deficient muscular dystrophy. Inset shows a higher
magnification of dy
3K/dy
3K triceps.
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Several strategies to combat disease in MDC1A mouse
models have been explored during the past decade.
Because the basement membrane is affected in MDC1A,
many of these approaches have targeted the expression
of ECM proteins. Transgenic expression of the laminin
a1a n da2 chains, mini-agrin, and cytotoxic T cell Gal-
Nac transferase have been found to compensate for
laminin a2 chain deficiency in mice [43,105,107-109].
Dy
W/dy
W mice bred to overexpress linker molecules (for
example, mini-agrin, full-length agrin, agrin-perlecan
fusion protein) between the laminin a4 chain and dys-
troglycan have a prolonged lifespan and significantly
improved muscle tissue. Importantly, it was also found
that mini-agrin can slow down the progression of dis-
ease at every stage [105,107,110]. The effects of laminin
a1 chain overexpression in the neuromuscular system
have also been extensively studied, and it has been
shown that dy
3K/dy
3K mice overexpressing the laminin
a1 chain have a near-normal lifespan and display con-
siderably improved muscle, heart and nerve morphology
and function [48,108,111] (Figure 7; see Additional
file 1). The reduction in muscle fibrosis was particularly
marked in these animals. Because transgenic expression
of laminin a1 chain reconstituted integrin a7 at the sar-
colemma [104], we reasoned that the laminin a1c h a i n
mediated reduction of laminin a2 chain deficient mus-
cular dystrophy mainly involves integrin a7b1( w h i c h
also binds laminin a1 chain with high affinity [112]).
Consistent with this notion, a laminin a1c h a i nd e v o i d
of the dystroglycan binding site but retaining the
integrin a7b1 binding domain significantly increased the
lifespan of dy
3K/dy
3K mice and partially rescued
dystrophic muscles, in particular the diaphragm [70].
However, subtle muscle defects (that is, residual degen-
eration) were seen in old animals overexpressing full-
length laminin a1 chain [111]. Hence, it is possible that
laminin a1 chain interactions with integrin a7b1a n d
dystroglycan might trigger different signaling cascades
to those triggered by the laminin a2 chain.
Despite significant therapeutic benefits in mice, it is
important to realize that these transgenic approaches
are not clinically feasible. Therefore, adenoassociated
virus-mediated gene transfer of mini-agrin was tested in
dy
W/dy
W and dy/dy mice. Notably, systemic gene deliv-
ery of mini-agrin improved the overall phenotype and
muscle function in treated animals [113].
Several approaches aimed at assuaging the secondary
defects in MDC1A, instead of targeting the primary
deficiency, have also been undertaken. As increased
apoptosis had been suggested to contribute to the
pathology of MDC1A, Miller et al. caused either inacti-
vation of the proapoptotic protein Bax or overexpression
of the antiapoptotic protein Bcl-2 in dy
W/dy
W animals
[114,115]; both of these genetic interventions improved
the health of the animals. Overexpression of Bcl-2 had
no major effect in dystrophin-deficient mice, indicating
that Bcl-2-mediated apoptosis is a more significant con-
tributor to the pathogenesis of MDC1A than that of
Duchenne muscular dystrophy [115]. The same group
also recently explored the use of anti-apoptotic pharma-
cologic treatment. Interestingly, treatment with minocy-
cline or doxycycline increased the lifespan of dy
W/dy
W
animals and lessened muscle pathology [116]. Similarly,
treatment with omigapil, which inhibits GAPDH-Siah1-
mediated apoptosis, ameliorated the pathological fea-
tures in dy
W/dy
W animals [93]. Recently, it was also
established that mitochondria isolated from dy
W/dy
W
muscle are swollen. This is a typical feature of abnormal
opening of the permeability transition pore caused by a
strong increase in intracellular calcium (which may be
detrimental for the muscle cell). Persistent opening may
cause mitochondrial rupture and subsequent cell death.
Laminin a2c h a i n - d e f i c i e n tdy
W/dy
W mice devoid of
cyclophilin-D, which is a regulatory protein of the per-
meability transition pore, displayed reduced muscular
dystrophy pathology [117]. Additionally, because
enhanced proteasomal degradation is a feature of lami-
nin a2 chain-deficient muscle [95], we hypothesized
that inhibition of the proteasome would lessen the myo-
pathology, and indeed, treatment with the proteasome
inhibitor MG-132 significantly improved the lifespan
and muscle morphology of dy
3K/dy
3K mice [95].
Finally, cell therapy has been evaluated in mouse mod-
els of MDC1A. Myoblast and CD90-positive cell
Figure 7 A2 - y e a r - o l dl a m i n i na2 chain-deficient mouse (dy
3K/
dy
3K) overexpressing laminin a1 chain, with a wild-type
littermate. Laminin a1 chain overexpression resulted in a
remarkable improvement of overall health and prevention of
muscular dystrophy that persisted throughout life.
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dy/dy and dy
3K/dy
3K mice, respectively, but no further
improvement in the animals, was reported [118,119].
However, bone-marrow transplantation improved life
span, growth rate, muscle strength and importantly,
respiratory function of dy/dy animals [120].
Altogether, considering that laminin a2c h a i nd e f i -
ciency seems to affect different cellular events, combina-
torial treatment strategies (for example, apoptosis and
proteasome inhibitors together with replacement ther-
apy) may be relevant for MDC1A. Moreover, bearing in
mind that MDC1A is associated with peripheral neuro-
pathy, therapies that also alleviate the neurologic dys-
function should be favored. Previous studies found that
motor nerve pathology could not be prevented by mus-
cle-specific expression of laminin a2c h a i n[ 4 3 ]a n d
mini-agrin [105], whereas ubiquitous expression of the
laminin a1 chain significantly reduced peripheral neuro-
pathy [48]. In addition, inactivation of Bax s [114] and
treatment with doxycycline [116] were reported to be
beneficial for the condition of motor neuron.
Conclusion
A great deal is known about the structure and function
of laminin-211, and advances concerning the develop-
ment of future therapies have been made for murine
laminin a2 chain-deficient muscular dystrophy. Absence
of the laminin a2 chain does not only affect skeletal
muscle but also several non-muscle tissues. Analysis of
these organs has been hampered by the relatively early
death of the animals. It would therefore be informative
to analyze the non-muscle organs in animals that have
been rescued from the muscle defects or to generate
mice with a tissue-specific disruption of the laminin a2
chain. Furthermore, the targeted genetic elimination of
individual laminin domains (in particular the LG
domains) would be valuable to understand their role
in vivo. Finally, elucidation of laminin a2c h a i n - i n d u c e d
signal transduction pathways is an important task. Such
studies would be helpful to further clarify the details of
laminin a2 chain function to design future treatment
for MDC1A.
Additional material
Additional file 1: Supplemental video 1. A 2-year-old laminin a2
chain-deficient mouse (dy
3K/dy
3K) overexpressing laminin a1 chain
together with a wild-type littermate. The rescue mouse is denoted
with a blue pointer at the beginning of the f. Both mice were placed in
a new cage. The dy
3KLMa1 mouse is as active as wild-type littermate; it
explores the cage and often stands up on its hind limbs.
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